Olfactory dysfunction in adult cystic fibrosis patients
Volume: 0 - Issue: 0
First page: 0 - Last page: 0
A. Minzoni - P. Orlando - L. Mazzetti - A. Ricchiuti - S. Bresci - G. Maggiore
DOI: 10.4193/Rhin25.243
Olfactory dysfunction (OD) is a frequent yet underrecognized manifestation of chronic rhinosinusitis (CRS) in cystic fibrosis (CF) (1). Despite widespread reports of OD in CF, the impact of CFTR modulator therapy on smell outcomes remains unclear. We conducted a prospective study to evaluate olfactory function changes in CF-related CRS patients, as defined by EPOS2020 (2), following 12 months of elexacaftor/tezacaftor/ivacaftor (ETI) therapy, exploring clinical and biological correlates. The study was approved by the local ethics committee (CEAVC 22454).
From 120 ETI-treated CF patients at the University Hospital of Careggi, 45 adults (mean age: 37.5 years; 55.6% female) diagnosed with CRS completed pre- and post-treatment assessments, including olfactory evaluation via the 16-item Sniffin’ Sticks Identification Test (SSIT) for its feasibility and longitudinal applicability.
Rhinology 0-0: 0-0, 0000
